Clinical practice guidelines for multigene assays in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
Open Access
- 21 September 2021
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 134 (19), 2269-2271
- https://doi.org/10.1097/cm9.0000000000001409
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 14 references indexed in Scilit:
- Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneBreast Cancer Research and Treatment, 2019
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerThe New England Journal of Medicine, 2018
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast CancerJAMA Oncology, 2018
- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast CancerJournal of Clinical Oncology, 2018
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline SummaryJournal of Oncology Practice, 2017
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerThe New England Journal of Medicine, 2016
- Prospective Validation of a 21-Gene Expression Assay in Breast CancerThe New England Journal of Medicine, 2015
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007Annals of Oncology, 2007
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004